Updates

Hutchison China Meditech - Nets US$20m upfront collaboration payment from Astra Zeneca

January 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

When we saw the shares leap 20% on an announcement of a drug licensing deal, our immediate reaction was that it must be the news we’ve been waiting for since April - the outlicencing deal for HMPL-004, a drug for inflammatory bowel disease, which is in phase II trials. But surprisingly not; instead, the news related to Volitinib (HMPL-504), an earlier stage drug that halts progress of breast and lung cancer. Ahead of Volitinib entering phase I testing, HCM has concluded a collaboration agreement to develop and commercialise it with AstraZeneca. Development costs in China will be shared with AstraZeneca, which has made an initial cash payment of $20m and will pay $120m contingent on milestones. ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

EMIS

Photo-Me - Cash pile goes to Â£51.1m

Hutchison China Meditech -NÃ©stle deal for HMPL-004 drug (January 2013)

Hutchison China Meditech (September 2012)

Hutchison China Meditech - 2012 starts with a bang (April 2012)

Hutchison China Meditech (March 2012)

Hutchison China Meditech - Broker says 600p sum of parts (September 2011)

Hutchison China Meditech - To distribute third party drugs (August 2011)

Hutchison China Meditech (April 2011)

Hutchison China Meditech - Pre-IPO funding ahead of NASDAQ float? (January 2011)

Hutchison China Meditech (October 2010)

Hutchison China Meditech - Out-licensing deal for lead product imminent (September 2010)

Hutchison China Meditech - Great secrecy shrouds R&D division (July 2010)

Hutchison China Meditech - 17 of 307 Chinese "essential medicines" (June 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X